Clinical Trial Update: Methylprednisolone in the Treatment of Patients With Signs of Severe Acute Respiratory Syndrome in Covid-19 [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating methylprednisolone for patients with severe acute respiratory syndrome related to SARS; completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syndrome
• Sars Coronavirus Infection

Drugs mentioned

• METHYLPREDNISOLONE (methylprednisolone)

Snippet

Sponsor: Fundação de Medicina Tropical Dr. Heitor Vieira Dourado | Conditions: SARS-CoV Infection, Severe Acute Respiratory Syndrome (SARS) Pneumonia | Phase 2 | Status: COMPLETED